| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LpPLA2 |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LpPLA2重组蛋白的3篇参考文献示例(注：文献信息为模拟示例，实际引用需核实)：
---
1. **文献名称**：*Expression and Purification of Recombinant Lp-PLA2 in Escherichia coli for Functional Studies*
**作者**：Smith J, et al.
**摘要**：研究报道了通过大肠杆菌系统高效表达重组人源Lp-PLA2蛋白，优化了纯化工艺并获得高活性蛋白，为后续酶学及抑制剂筛选提供基础材料。
2. **文献名称**：*Crystal Structure of Recombinant Lp-PLA2 Reveals Insights into Its Catalytic Mechanism*
**作者**：Chen L, et al.
**摘要**：利用重组Lp-PLA2蛋白解析了其晶体结构，揭示了底物结合口袋的关键氨基酸残基，阐明了其水解氧化磷脂的分子机制，为靶向药物设计提供结构基础。
3. **文献名称**：*Role of Recombinant Lp-PLA2 in Macrophage Inflammation and Atherosclerosis Development*
**作者**：Wang Y, et al.
**摘要**：通过体外实验证实重组Lp-PLA2可促进巨噬细胞炎症因子释放，并在动脉粥样硬化小鼠模型中加剧斑块形成，提示其作为治疗靶点的潜在价值。
---
(注：以上为示例模板，实际文献需通过学术数据库检索确认。)建议使用关键词 **"recombinant Lp-PLA2"** 在PubMed或Web of Science中筛选近年研究。
**Background of Lp-PLA2 Recombinant Protein**
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH), is an enzyme encoded by the *PLA2G7* gene. It is primarily secreted by macrophages and other inflammatory cells, circulating in plasma bound to lipoproteins, particularly low-density lipoprotein (LDL). Lp-PLA2 hydrolyzes oxidized phospholipids in LDL, generating pro-inflammatory mediators like lysophosphatidylcholine and oxidized free fatty acids, which contribute to vascular inflammation and atherosclerosis.
Due to its role in plaque destabilization, Lp-PLA2 has emerged as a biomarker for cardiovascular disease (CVD) risk assessment. Elevated Lp-PLA2 levels correlate with increased risk of atherosclerosis, myocardial infarction, and stroke. However, its dual role—protective in hydrolyzing pro-inflammatory PAF but detrimental in promoting plaque vulnerability—has spurred debate about its therapeutic targeting.
Recombinant Lp-PLA2 proteins are produced via genetic engineering in expression systems (e.g., *E. coli* or mammalian cells) to study its structure, function, and inhibition. These proteins retain enzymatic activity, enabling research into mechanisms linking Lp-PLA2 to CVD and neurodegenerative diseases like Alzheimer’s. They also serve as antigens for diagnostic assay development or to generate antibodies.
Pharmaceutical interest in Lp-PLA2 inhibitors (e.g., darapladib) for CVD treatment has driven demand for high-purity recombinant protein to screen compounds or validate drug efficacy. Despite mixed clinical trial outcomes, Lp-PLA2 remains a focus for therapeutic exploration, underscoring the importance of recombinant variants in both basic research and translational applications.
In summary, recombinant Lp-PLA2 proteins are vital tools for unraveling the enzyme’s pathophysiological roles and advancing targeted therapies for inflammatory diseases.
×
